Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Jul 30, 2024 6:35pm
188 Views
Post# 36155227

Apologies

Apologies My apologies for not spell checking. Posting from a phone. My last post revised below:

 
 
Management drops the ball
 
I am still dumbfounded regarding the $600,000 private place announced last night at $1.50
 
This should not come as a surprise regarding a private placement to raise funds. The company financials and the market knew the company had to raise capital at some point, as they will again when we move to phase 3 trial.
 
As I mentioned yesterday the share price is down 30% in the past 12 months.
 
I would hope that management knew they had to raise capital in 2024. Did they have a plan in place to do this raise? 
 
I am not sure they did? The share price was at $2.52 just a few months ago with mutiple positive news releases.
 
Why did they not time the raise around news releases?
 
They did do a similar private placement at $1.50 back in 2020. Look at what the company has accomplished since 2020 yet they slap shareholders in the face by doing another raise in 2024 at $1.50. 
 
The 2024 Arch is a much stronger company with much lower risk yet management made the decision to do a raise at $1.50, the same price they did in 2020. Is that what management feels the value of Arch is?
 
This company has always had an issue with communication. This company is not  well known and that is reflected daily volume with a lack of buyers. 
 
What has this company done to promote the science and their success story other than news releases. 
 
Has management ever attended target specific conferences with a target audience? Has this company engaged larger institutions who have large high networth clients? As I have previously mentioned, management has done many positive things but they have failed at creating investor awareness, shareholder value, promoting the story and driving buyers into the markets.
 
There is absolutely no logical reason why they waited to raise money at $1.50 yesterday, there were many missed opportunities at higher share price. 
 
This comes across as an act of desperation.
 
When the share price was at $2.40 to $2.50 they could have easily raised money at a discount but chose not to at $2 to $2.20
 
The CEO purchased shares in the open market at $1.75, they could have raised money at that time to demonstrate that even CEO thinks price is too low at $1.75 but no they chose to do nothing.
 
They decided to wait until the share price was at $1.50
 
Management must have known they were going to do raise. Why didnt they engage a marketing plan prior to the raise to get the buyers into the market and drive the share price higher. Why didnt they wait until material news release to time it.
 
Unfortunately this falls back on management and their decision and timing to do this raise just as the lack of buyers and lack of exposure does.
<< Previous
Bullboard Posts
Next >>